Xu Xiaoxiao, Wang Zhenxing, Yu Yong, Wang Yafei, Zhang Lianyu, Sun Baocun, Da Wanming, Zhang Yizhuo
Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
J Gastroenterol Hepatol. 2014 Sep;29(9):1678-84. doi: 10.1111/jgh.12615.
This study was undertaken to evaluate the clinical characteristics, prognostic factors, and long-term outcomes of patients with mucosa-associated lymphoid tissue (MALT) lymphoma in the gastrointestinal (GI) tract.
Clinical and pathological features of patients with MALT lymphoma in the GI tract, who were treated consecutively at Tianjin Medical University Cancer Institute and Hospital from 2001 to 2011, were evaluated retrospectively.
Among a total of 99 identified cases, 79.79% of lymphomas were localized in the stomach, 20.20% in the intestinal tract, and disseminated disease was detected in 35.4% of cases. The estimated 5-year overall survival (OS) and 5-year progression-free survival (PFS) rates were 73.1% and 65.1%, respectively. The comparison between stomach and intestinal tract lymphomas demonstrated no significant difference in characteristics, but nodal involvement was significantly lower in gastric MALT lymphoma (26.6%) as compared with intestinal tract MALT lymphoma (60%, P = 0.006). The outcomes of gastric and intestinal MALT lymphomas were similar (OS, P = 0.492; PFS, P = 0.408), and so was the survival between proximal and distal gastric lymphomas (OS, P = 0.077; PFS, P = 0.181). Serum lactate dehydrogenase level above normal was identified as the only adverse prognostic factor for both OS and PFS.
The clinical characteristics and outcomes demonstrated no significant differences between gastric and intestinal tract MALT lymphomas. Serum lactate dehydrogenase level was an independent prognostic factor for the survival of GI MALT lymphoma.
本研究旨在评估胃肠道黏膜相关淋巴组织（MALT）淋巴瘤患者的临床特征、预后因素及长期结局。
回顾性分析2001年至2011年在天津医科大学肿瘤医院连续接受治疗的胃肠道MALT淋巴瘤患者的临床和病理特征。
在总共99例确诊病例中，79.79%的淋巴瘤局限于胃，20.20%位于肠道，35.4%的病例出现播散性疾病。估计的5年总生存率（OS）和5年无进展生存率（PFS）分别为73.1%和65.1%。胃和肠道淋巴瘤在特征上无显著差异，但胃MALT淋巴瘤的淋巴结受累率（26.6%）显著低于肠道MALT淋巴瘤（60%，P = 0.006）。胃和肠道MALT淋巴瘤的结局相似（OS，P = 0.492；PFS，P = 0.408），胃近端和远端淋巴瘤的生存率也相似（OS，P = 0.077；PFS，P = 0.181）。血清乳酸脱氢酶水平高于正常被确定为OS和PFS的唯一不良预后因素。
胃和肠道MALT淋巴瘤的临床特征和结局无显著差异。血清乳酸脱氢酶水平是胃肠道MALT淋巴瘤生存的独立预后因素。
